BTAI (BioXcel) רווח נקי למניה (EPS TTM)

BioXcel Therapeutics (BTAI) is implementing neural networks to rapidly identify new applications for existing medications. The company focuses on psychosis therapy, offering the drug IGALMI to clinics to assist patients with dementia. Currently, the business is developing the commercial launch of a treatment for acute agitation in bipolar disorders. Serving as the primary valuation tool, this price chart demonstrates an EPS TTM of 66.40.

Analyzing profit resilience during stress phases is critical for long-term risk management, measured via the dynamics of trailing twelve-month earnings per share. The current EPS TTM YoY growth rate reflects the ability of BioXcel Therapeutics (BTAI) to monetize its AI patents under strict FDA oversight, determining the business's actual margin of safety amidst a high regulatory burden.